Published 1987 | Version v1
Book

Assessment of tumor control following definitive radiotherapy in carcinoma of the prostate: A continuing dilemma

  • 1. Washington Univ. School of Medicine, Div. of Radiation Oncology, St. Louis, MO (USA)

Description

Evaluation of tumor response and tumor control after definitive radiotherapy is a relatively simple task in most malignancies arising at sites amenable to clinical examination (inspection and palpation). The rates of tumor regression following irradiation are quite variable. While some types of cancer regress completely during the radiotherapy course, some may take weeks or months to resolve. Occasionally, residual induration or a residual mass may persist for prolonged periods (many months), prompting the clinician to consider a biopsy for evaluation of the tumor status. In these circumstances histological examination may show necrotic tumor or residual fibrotic tissue. Finding viable-appearing tumor cells beyond the immediate postirradiation period (several weeks to a few months after completion of the radiotherapy course) is generally accepted as an equivalent of failure to eradicate the tumor. However, in a few types of cancer, presence of histologically identifiable and apparently viable tumor cells over protracted periods does not necessarily imply treatment failure

Additional details

Publishing Information

Publisher
Alan R. Liss Inc.
Imprint Place
New York, NY (USA)
ISBN
0-8451-5089-8
Imprint Title
Current concepts and approaches to the study of prostrate cancer
Imprint Pagination
812 p.
Journal Page Range
p. 681-692.

Conference

Title
Current concepts and approaches to the study of prostate cancer.
Dates
18-20 Oct 1985.
Place
Prouts Neck, ME (USA).

INIS

Country of Publication
United States
Country of Input or Organization
United States
INIS RN
21007453
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Resource subtype / Literary indicator
Conference
Descriptors DEI
CARCINOMAS; FAILURES; HISTOLOGY; MONITORING; PROSTATE; RADIOTHERAPY
Descriptors DEC
BODY; DISEASES; GLANDS; MALE GENITALS; MEDICINE; NEOPLASMS; ORGANS; THERAPY

Optional Information

Secondary number(s)
CONF-8510509--.